UBS Group’s T-REX 2X Inverse CRCL Daily Target ETF CRCD Stock Holding History

UBS Group’s Portfolio CRCD Stock Details CRCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-963	Closed	-$33.1K	–	11728
2025 Q4	$33.1K	Buy	+963	New	+$29.2K	﹤0.01%	7467

Other funds holding CRCD

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group's CRCD Position: Q1 2026 in Review

UBS Group sold out of T-REX 2X Inverse CRCL Daily Target ETF (CRCD) in Q1 2026, closing a stake of 963 shares — an estimated $33.1K sold.

UBS Group first reported a position in CRCD in Q4 2025 and held it in 1 quarter. The position peaked at $33.1K in Q4 2025. 8 funds tracked by Wall St. Rank hold CRCD as of Q1 2026.

UBS Group reported no remaining T-REX 2X Inverse CRCL Daily Target ETF position as of Q1 2026 after selling out during the quarter.
UBS Group sold 963 T-REX 2X Inverse CRCL Daily Target ETF shares in Q1 2026, an estimated $33.1K.
UBS Group first reported a position in T-REX 2X Inverse CRCL Daily Target ETF in Q4 2025 and held it in 1 quarter.
UBS Group's T-REX 2X Inverse CRCL Daily Target ETF position peaked at $33.1K in Q4 2025.
8 funds tracked by Wall St. Rank held T-REX 2X Inverse CRCL Daily Target ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.